Year in Review: Rheumatic Disease Research in 2019

ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: 2019 ACR/ARP Annual Meeting Conditions Osteoarthritis bone fracture JAK inhibitors Knee Osteoarthritis (OA) physical activity psoriatic arthritis Research Source Type: research